Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Notes Payables: 2018-2025

Historic Notes Payables for Dr Reddys Laboratories (RDY) over the last 8 years, with Mar 2025 value amounting to $445.0 million.

  • Dr Reddys Laboratories' Notes Payables rose 190.85% to $445.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $445.0 million, marking a year-over-year increase of 190.85%. This contributed to the annual value of $445.0 million for FY2025, which is 190.85% up from last year.
  • According to the latest figures from FY2025, Dr Reddys Laboratories' Notes Payables is $445.0 million, which was up 190.85% from $153.0 million recorded in FY2024.
  • Over the past 5 years, Dr Reddys Laboratories' Notes Payables peaked at $445.0 million during FY2025, and registered a low of $90.0 million during FY2023.
  • Over the past 3 years, Dr Reddys Laboratories' median Notes Payables value was $153.0 million (recorded in 2024), while the average stood at $229.3 million.
  • In the last 5 years, Dr Reddys Laboratories' Notes Payables slumped by 74.79% in 2023 and then soared by 190.85% in 2025.
  • Yearly analysis of 5 years shows Dr Reddys Laboratories' Notes Payables stood at $316.0 million in 2021, then climbed by 12.97% to $357.0 million in 2022, then plummeted by 74.79% to $90.0 million in 2023, then skyrocketed by 70.00% to $153.0 million in 2024, then surged by 190.85% to $445.0 million in 2025.